Zenflow

We’re developing a better treatment for the up to 400 million men worldwide who suffer from urinary obstruction related to benign prostatic hyperplasia (BPH or enlarged prostate). We aim to give men a new option that relieves symptoms permanently without requiring a painful, invasive procedure and risking serious complications.

Fourteen million men in the US and over 200 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). The majority of men will experience symptoms of this disease at some point in life. BPH, also known as prostate enlargement, leads to urinary straining, frequency, urgency, and sleep disruption. Despite the high prevalence and significant quality of life burden of BPH, established treatments are limited to drugs, which have limited effectiveness, and surgery, which carries a high risk of sexual side effects. The Innoflow device uses a mechanism known to relieve BPH symptoms with a unique design that enables it to avoid the complications associated with prior solution attempts. Urologists can deploy the device in a simple, office-based procedure that is faster and more painless than any existing therapy.

Website

Headquarters

South San Francisco, CA

Year founded

2014

Company type

Privately Held

Company size

11-50 employees

Specialties

Medical Devices and Benign Prostatic Hyperplasia

ZenFlow is also backed by Invus Opportunities, Medical Technology Venture Partners, Shangbay Capital, Stanford-StartX Fund, F-Prime Capital Partners